Nektar Therapeutics (NKTR) Competitors $1.27 +0.01 (+0.79%) (As of 09/19/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends NKTR vs. ADCT, MCRB, AVIR, PCRX, OMER, ASMB, CPIX, AGIO, LLY, and JNJShould you be buying Nektar Therapeutics stock or one of its competitors? The main competitors of Nektar Therapeutics include ADC Therapeutics (ADCT), Seres Therapeutics (MCRB), Atea Pharmaceuticals (AVIR), Pacira BioSciences (PCRX), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Agios Pharmaceuticals (AGIO), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "medical" sector. Nektar Therapeutics vs. ADC Therapeutics Seres Therapeutics Atea Pharmaceuticals Pacira BioSciences Omeros Assembly Biosciences Cumberland Pharmaceuticals Agios Pharmaceuticals Eli Lilly and Company Johnson & Johnson Nektar Therapeutics (NASDAQ:NKTR) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, community ranking, risk and media sentiment. Do analysts prefer NKTR or ADCT? Nektar Therapeutics currently has a consensus price target of $1.50, indicating a potential upside of 18.11%. ADC Therapeutics has a consensus price target of $9.00, indicating a potential upside of 180.37%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than Nektar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nektar Therapeutics 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20ADC Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has more volatility & risk, NKTR or ADCT? Nektar Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Does the media prefer NKTR or ADCT? In the previous week, Nektar Therapeutics had 1 more articles in the media than ADC Therapeutics. MarketBeat recorded 2 mentions for Nektar Therapeutics and 1 mentions for ADC Therapeutics. ADC Therapeutics' average media sentiment score of 1.00 beat Nektar Therapeutics' score of 0.35 indicating that ADC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ADC Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in NKTR or ADCT? Nektar Therapeutics received 574 more outperform votes than ADC Therapeutics when rated by MarketBeat users. Likewise, 70.64% of users gave Nektar Therapeutics an outperform vote while only 65.85% of users gave ADC Therapeutics an outperform vote. CompanyUnderperformOutperformNektar TherapeuticsOutperform Votes62870.64% Underperform Votes26129.36% ADC TherapeuticsOutperform Votes5465.85% Underperform Votes2834.15% Do insiders & institutionals believe in NKTR or ADCT? 75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 3.7% of Nektar Therapeutics shares are held by insiders. Comparatively, 4.1% of ADC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has better earnings & valuation, NKTR or ADCT? ADC Therapeutics has lower revenue, but higher earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNektar Therapeutics$93.16M2.51-$276.06M-$0.92-1.38ADC Therapeutics$66.75M3.98-$240.05M-$2.75-1.17 Is NKTR or ADCT more profitable? Nektar Therapeutics has a net margin of -190.09% compared to ADC Therapeutics' net margin of -323.60%. ADC Therapeutics' return on equity of 0.00% beat Nektar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nektar Therapeutics-190.09% -133.64% -42.03% ADC Therapeutics -323.60%N/A -57.54% SummaryADC Therapeutics beats Nektar Therapeutics on 10 of the 18 factors compared between the two stocks. Ad Unstoppable ProsperityMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a row! But – knowing what the options trading landscape looks like, and what you're up against is a must.So make sure you claim your free seat by clicking here now. Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NKTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat are MarkeBeat Followers?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKTR vs. The Competition Export to ExcelMetricNektar TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$233.71M$7.60B$5.53B$8.46BDividend YieldN/A4.44%4.96%4.06%P/E Ratio-1.3819.21147.3618.88Price / Sales2.51341.621,681.6284.21Price / CashN/A37.6337.1531.47Price / Book1.845.964.954.56Net Income-$276.06M$153.00M$114.92M$225.32M7 Day Performance-3.05%8.24%9.02%4.19%1 Month Performance-0.78%21.14%15.50%7.96%1 Year Performance78.87%27.37%33.13%15.09% Nektar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADCTADC Therapeutics3.5584 of 5 stars3.56 / 5 stars$3.24+4.5%$9.00+177.8%+301.3%$268.20M$66.75M-1.18310Short Interest ↓News CoveragePositive NewsGap UpMCRBSeres Therapeutics4.069 of 5 stars4.07 / 5 stars$1.06+0.5%$5.08+381.8%-62.1%$159.78M$374,000.00-1.76330Gap DownAVIRAtea Pharmaceuticals2.9577 of 5 stars2.96 / 5 stars$3.90-2.3%$6.88+76.4%+17.5%$328.47M$351.37M-1.9970Insider SellingAnalyst RevisionNews CoveragePCRXPacira BioSciences4.7603 of 5 stars4.76 / 5 stars$14.94+2.0%$24.78+65.8%-56.1%$695.40M$690.31M10.45720OMEROmeros0.8749 of 5 stars0.87 / 5 stars$4.20+6.9%N/A+30.4%$243.37MN/A-2.13198Gap UpASMBAssembly Biosciences2.1126 of 5 stars2.11 / 5 stars$18.75+3.2%N/A+64.0%$119.06M$7.16M0.00100Gap UpCPIXCumberland Pharmaceuticals1.4069 of 5 stars1.41 / 5 stars$1.30+4.0%N/A-39.3%$18.45M$37.79M-2.2080AGIOAgios Pharmaceuticals2.6497 of 5 stars2.65 / 5 stars$47.47+4.2%$51.33+8.1%+89.0%$2.70B$31.31M-7.51390Analyst ForecastNews CoverageGap UpLLYEli Lilly and Company4.571 of 5 stars4.57 / 5 stars$911.60+0.7%$977.35+7.2%+59.2%$866.39B$38.92B134.2643,000JNJJohnson & Johnson4.7959 of 5 stars4.80 / 5 stars$165.31-0.5%$173.21+4.8%+1.6%$397.85B$86.58B10.31131,900Short Interest ↑ Related Companies and Tools Related Companies: ADCT Competitors MCRB Competitors AVIR Competitors PCRX Competitors OMER Competitors ASMB Competitors CPIX Competitors AGIO Competitors LLY Competitors JNJ Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NKTR) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersAct by Friday, August 16th, to collect this 22% dividendLet's do a little math here... To double your money at a 3% rate of return, you would need around 23 years....Investors Alley | SponsoredWhy You Should NOT Trade This MarketYou'll be interested in our 5-Day Options Trading Challenge, starting September 23. So, what makes this dif...InvestorPlace | SponsoredNew September Stock WarningSeptember is the most volatile month of the year for stocks. And after the brutal tech selloff, one Wall St...Chaikin Analytics | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NKTR Stock Alerts